Treatment with immune checkpoint inhibitors targeted against programmed cell death 1 (PD‐1) and programmed cell death ligand 1 (PD‐L1) have demonstrated prolonged survival for some types of cancer.1 The gene discussed is PDCD1; the disease is cancer.